Company profile: Umoja Biopharma
1.1 - Company Overview
Company description
- Provider of next-generation immunotherapies intended to combat cancer.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Umoja Biopharma
T3 Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of innovative bacterial cancer therapies using engineered live bacteria to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment. Offers a proprietary bacterial cancer therapy platform and develops T3P-Y058-739, a lead candidate delivering proteins into solid tumors to induce a specific immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3 Pharmaceuticals company profile →
Admune Therapeutics
HQ: United States
Website
- Description: Provider of development and delivery of cytokine therapy drugs for cancer as a clinical-stage biotech company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Admune Therapeutics company profile →
AnPac Bio
HQ: United States
Website
- Description: Provider of early cancer screening and detection services, offering the CDA Early Cancer Risk Assessment using Cancer Differentiation Analysis to evaluate early cancer risks, the APCS Pan-Cancer Screening to detect multiple cancer types, and the ADME Third Immune Defense Test to assess immune defense capabilities against diseases, including cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AnPac Bio company profile →
MAIA Biotechnology
HQ: United States
Website
- Description: Provider of immuno-oncology drug R&D, developing first-in-class therapies with novel mechanisms, including THIO, an investigational telomere-targeting candidate that induces immune responses in cancer cells (Phase 2 in non-small cell lung cancer), and second-generation telomere-targeting agents in early discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MAIA Biotechnology company profile →
Immix Biopharma
HQ: United States
Website
- Description: Provider of oncology and inflammation-driven therapeutics and platforms, including NXC-201, a BCMA-targeted CAR-T in Phase 1b/2a for relapsed/refractory AL amyloidosis and multiple myeloma, and IMX-110, a tissue-specific therapy in Phase 1b/2a for advanced solid tumors. Develops the N-GENIUS Cell Therapy Platform (EXPAND) and SMARxT platform, plus TME and Immune Normalization technologies to enhance CAR-T and address pathologic inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immix Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Umoja Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Umoja Biopharma
2.2 - Growth funds investing in similar companies to Umoja Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Umoja Biopharma
4.2 - Public trading comparable groups for Umoja Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →